Novartis Campus and Clinical Updates: Del-Brax Phase I/II Study Results in Basel
The Novartis Campus in Basel remains a prominent hub for architectural innovation and corporate life, reflecting the ongoing global developments driven by its parent organization. While visitors explore the contemporary buildings and landscaped public spaces created by leading international architects, the organization itself continues to advance major medical research initiatives originating from its headquarters.
Clinical Milestones in Neuromuscular Research
Recent announcements from the organization highlight significant progress in the FORTITUDE Phase I/II study evaluating delpacibart braxlosiran (del-brax). Designed to address facioscapulohumeral muscular dystrophy (FSHD), the investigational therapy met its primary and key secondary biomarker endpoints, showing reductions in specific biomarker levels associated with target engagement and muscle protection.
As the broader neuromuscular pipeline expands following the recent acquisition of Avidity Biosciences, research teams are continuing to engage with global regulatory authorities. Ongoing developments, including the recruitment phase for subsequent studies such as FORTITUDE-3, underscore the continued focus on targeted RNA therapeutics and rare disease treatments.
To learn more about local cultural highlights and upcoming architectural exhibitions in the area, check out what's on exhibitions or explore the interactive map view on Musemap (musemap.art).
